Last reviewed · How we verify

Bevacizumab + Deferred Aflibercept Group

Jaeb Center for Health Research · Phase 3 active Small molecule

Bevacizumab + Deferred Aflibercept Group is a Anti-angiogenic agents; VEGF inhibitors Small molecule drug developed by Jaeb Center for Health Research. It is currently in Phase 3 development for Metastatic colorectal cancer (bevacizumab established; aflibercept deferred strategy investigational), Potentially other solid tumors with VEGF-dependent angiogenesis. Also known as: Avastin.

This combination uses bevacizumab (an anti-VEGF monoclonal antibody) with deferred aflibercept (a VEGF trap) to inhibit vascular endothelial growth factor signaling, reducing abnormal blood vessel formation.

This combination uses bevacizumab (an anti-VEGF monoclonal antibody) with deferred aflibercept (a VEGF trap) to inhibit vascular endothelial growth factor signaling, reducing abnormal blood vessel formation. Used for Metastatic colorectal cancer (bevacizumab established; aflibercept deferred strategy investigational), Potentially other solid tumors with VEGF-dependent angiogenesis.

At a glance

Generic nameBevacizumab + Deferred Aflibercept Group
Also known asAvastin
SponsorJaeb Center for Health Research
Drug classAnti-angiogenic agents; VEGF inhibitors
TargetVEGF-A (bevacizumab); VEGF-A, VEGF-B, PlGF (aflibercept)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Bevacizumab is a humanized monoclonal antibody that binds and neutralizes VEGF-A, preventing its interaction with VEGF receptors on endothelial cells. Aflibercept is a soluble VEGF receptor fusion protein that acts as a decoy receptor, trapping VEGF ligands. The deferred strategy involves sequential or conditional use of aflibercept after bevacizumab, potentially managing resistance or optimizing anti-angiogenic therapy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bevacizumab + Deferred Aflibercept Group

What is Bevacizumab + Deferred Aflibercept Group?

Bevacizumab + Deferred Aflibercept Group is a Anti-angiogenic agents; VEGF inhibitors drug developed by Jaeb Center for Health Research, indicated for Metastatic colorectal cancer (bevacizumab established; aflibercept deferred strategy investigational), Potentially other solid tumors with VEGF-dependent angiogenesis.

How does Bevacizumab + Deferred Aflibercept Group work?

This combination uses bevacizumab (an anti-VEGF monoclonal antibody) with deferred aflibercept (a VEGF trap) to inhibit vascular endothelial growth factor signaling, reducing abnormal blood vessel formation.

What is Bevacizumab + Deferred Aflibercept Group used for?

Bevacizumab + Deferred Aflibercept Group is indicated for Metastatic colorectal cancer (bevacizumab established; aflibercept deferred strategy investigational), Potentially other solid tumors with VEGF-dependent angiogenesis.

Who makes Bevacizumab + Deferred Aflibercept Group?

Bevacizumab + Deferred Aflibercept Group is developed by Jaeb Center for Health Research (see full Jaeb Center for Health Research pipeline at /company/jaeb-center-for-health-research).

Is Bevacizumab + Deferred Aflibercept Group also known as anything else?

Bevacizumab + Deferred Aflibercept Group is also known as Avastin.

What drug class is Bevacizumab + Deferred Aflibercept Group in?

Bevacizumab + Deferred Aflibercept Group belongs to the Anti-angiogenic agents; VEGF inhibitors class. See all Anti-angiogenic agents; VEGF inhibitors drugs at /class/anti-angiogenic-agents-vegf-inhibitors.

What development phase is Bevacizumab + Deferred Aflibercept Group in?

Bevacizumab + Deferred Aflibercept Group is in Phase 3.

What are the side effects of Bevacizumab + Deferred Aflibercept Group?

Common side effects of Bevacizumab + Deferred Aflibercept Group include Hypertension, Proteinuria, Bleeding, Thromboembolic events, Gastrointestinal perforation, Wound healing complications.

What does Bevacizumab + Deferred Aflibercept Group target?

Bevacizumab + Deferred Aflibercept Group targets VEGF-A (bevacizumab); VEGF-A, VEGF-B, PlGF (aflibercept) and is a Anti-angiogenic agents; VEGF inhibitors.

Related